[go: up one dir, main page]

WO2003018006A1 - Porphyrin-zinc oxide complex and use of the same as photosensitive medicament which exitates photodynamic action by radiation and the use thereof in targeted therapy - Google Patents

Porphyrin-zinc oxide complex and use of the same as photosensitive medicament which exitates photodynamic action by radiation and the use thereof in targeted therapy Download PDF

Info

Publication number
WO2003018006A1
WO2003018006A1 PCT/CN2002/000595 CN0200595W WO03018006A1 WO 2003018006 A1 WO2003018006 A1 WO 2003018006A1 CN 0200595 W CN0200595 W CN 0200595W WO 03018006 A1 WO03018006 A1 WO 03018006A1
Authority
WO
WIPO (PCT)
Prior art keywords
porphyrin
radiation
zinc oxide
complex
exitates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2002/000595
Other languages
French (fr)
Chinese (zh)
Inventor
Guochen Dong
Wenshuai Dong
Jing Dong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2003018006A1 publication Critical patent/WO2003018006A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a porphyrin-zinc oxide complex which is a novel photosensitive compound, wherein zinc-oxygen complex unit is introduced in the molecular structure of porphyrin compound or its derivatives. The present invention also provides the use of such porphyrin derivatives as photosensitizer in treatment of tumour etc., that is, by virtue of its retention property in tumour tissue, radiation (include for example X-radiation) with different wavelength and intensity is selected to make the wavelength of the secondary excitation visible light which is radiated by zinc-oxygen complex matched with the Soret peak of porphyrin derivatives'absortion light. The said complex can replace current laser therapy, minimize the body lesion by radiation and damage of normal tissue by photodynamic action.
PCT/CN2002/000595 2001-08-27 2002-08-27 Porphyrin-zinc oxide complex and use of the same as photosensitive medicament which exitates photodynamic action by radiation and the use thereof in targeted therapy Ceased WO2003018006A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN 01132609 CN1336174A (en) 2001-08-27 2001-08-27 Anticancer compoiste light ball with X-ray stimulated zinc oxide-porphyrin compound
CN01132609.3 2001-08-27

Publications (1)

Publication Number Publication Date
WO2003018006A1 true WO2003018006A1 (en) 2003-03-06

Family

ID=4671489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2002/000595 Ceased WO2003018006A1 (en) 2001-08-27 2002-08-27 Porphyrin-zinc oxide complex and use of the same as photosensitive medicament which exitates photodynamic action by radiation and the use thereof in targeted therapy

Country Status (2)

Country Link
CN (1) CN1336174A (en)
WO (1) WO2003018006A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008023228A1 (en) 2008-05-08 2009-11-19 Technische Universität Dresden Nanoparticle comprising piezoelectric, pyroelectric or ferroelectric crystalline core material with electric dipole properties, useful as an agent for selective tissue therapy
US11850233B2 (en) 2019-10-28 2023-12-26 Matibur Rahaman Zamadar Reduced adaptive microbial resistance treatment for flesh eating disease (necrotizing fasciitis)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1336174A (en) * 2001-08-27 2002-02-20 董国臣 Anticancer compoiste light ball with X-ray stimulated zinc oxide-porphyrin compound
WO2004067508A2 (en) * 2003-01-24 2004-08-12 The Research Foundation Of State University Of Newyork Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
CN103721257B (en) * 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 Phytochrome catalytic decomposition hydrogen peroxide medicine series
CN105664379B (en) * 2016-03-02 2019-07-26 中国人民解放军第四军医大学 A deep tumor treatment system with photodynamic combined radiotherapy
CN105797278B (en) * 2016-03-02 2018-08-21 中国人民解放军第四军医大学 Toy excitation of X-rays fluorescent imaging and optical dynamic therapy combined unit and method
CN117018191A (en) * 2023-09-05 2023-11-10 上海市浦东新区人民医院 Zinc oxide-protoporphyrin nano-composite and preparation method and application thereof
CN117065019A (en) * 2023-09-28 2023-11-17 常州大学 A chlorin e6 nanocluster that can be activated by X-rays and its preparation method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN88100621A (en) * 1988-02-12 1988-09-07 董国臣 In vivo photodynamic action of anticancer immunosynthetic agents
CN1296949A (en) * 1999-11-17 2001-05-30 中国科学院长春物理研究所 Process for synthesizing benzoporphyrin zinc complex
CN1336174A (en) * 2001-08-27 2002-02-20 董国臣 Anticancer compoiste light ball with X-ray stimulated zinc oxide-porphyrin compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN88100621A (en) * 1988-02-12 1988-09-07 董国臣 In vivo photodynamic action of anticancer immunosynthetic agents
CN1296949A (en) * 1999-11-17 2001-05-30 中国科学院长春物理研究所 Process for synthesizing benzoporphyrin zinc complex
CN1336174A (en) * 2001-08-27 2002-02-20 董国臣 Anticancer compoiste light ball with X-ray stimulated zinc oxide-porphyrin compound

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008023228A1 (en) 2008-05-08 2009-11-19 Technische Universität Dresden Nanoparticle comprising piezoelectric, pyroelectric or ferroelectric crystalline core material with electric dipole properties, useful as an agent for selective tissue therapy
US11850233B2 (en) 2019-10-28 2023-12-26 Matibur Rahaman Zamadar Reduced adaptive microbial resistance treatment for flesh eating disease (necrotizing fasciitis)

Also Published As

Publication number Publication date
CN1336174A (en) 2002-02-20

Similar Documents

Publication Publication Date Title
Kübler Photodynamic therapy
Mahmoud et al. Effects of visible light on the skin
Choudhary et al. Photodynamic therapy in dermatology: a review
Alex Hsi et al. Photodynamic therapy in the treatment of cancer: current state of the art
Spikes et al. Photodynamic therapy of tumours and other diseases using porphyrins
Gluckman Hematoporphyrin photodynamic therapy: is there truly a future in head and neck oncology? Reflections on a 5‐year experience
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
Wennberg et al. Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp
WO2004002476A3 (en) Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
Calzavara‐Pinton et al. Photodynamic therapy: update 2006 Part 2: Clinical results
WO2003032901A3 (en) Pathological tissue detection and treatment employing targeted benzoindole optical agents
Stell et al. Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5‐aminolaevulinic acid
Allison et al. A clinical review of PDT for cutaneous malignancies
Kessel et al. Photodynamic effects: porphyrin vs chlorin
WO2003032900A3 (en) Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
Xiang et al. A review of light sources and enhanced targeting for photodynamic therapy
WO2003018006A1 (en) Porphyrin-zinc oxide complex and use of the same as photosensitive medicament which exitates photodynamic action by radiation and the use thereof in targeted therapy
US6887862B2 (en) Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy
WO2001024825A3 (en) Significance of dosimetry in photodynamic therapy of injured arteries
CA2112444A1 (en) Medical Laser Apparatus and Diagnosing/Curing Apparatus Using the Medical Laser Apparatus
Baptista et al. Our PDT experience in the treatment of non‐melanoma skin cancer over the last 7 years
AU2002314846A1 (en) Method for improving treatment selectivity and efficacy using intravascular photodynamic therapy
WO2005048944A3 (en) Activatable photodynamic therapy agents
Silva et al. Photodynamic therapy: dermatology and ophthalmology as main fields of current applications in clinic

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP